Cytiva, formerly part of GE Healthcare Life Sciences, has completed an extensive renovation to its Fast Trak cGMP contract biomanufacturing and process development site in Marlborough, MA. The upgraded facility is 60,000 square feet and has bioprocessing capabilities ranging in scale from 10L to 2000L. Biotechnology companies looking for assistance in bringing therapeutics to market faster can leverage the extensive technical support and single-use biomanufacturing expertise available at this enhanced site.
 
“Biotechnology companies are increasingly outsourcing their manufacturing, whether to access expertise, capacity, or both,” said Olivier Loeillot, senior vice president, bioprocess, Cytiva. “Our upgraded Fast Trak cGMP facility will provide our customers, particularly the small to mid-size companies, with the services and expertise needed to help expedite their processes and get to market faster.”
 
Cytiva’s Fast Trak services team has been accelerating customer projects for more than 17 years, completing more than one hundred production campaigns in one of six global biomanufacturing sites. Outsourcing the development of enhanced processing platforms can streamline tech transfer and accelerate capacity expansion programs. With an extensive understanding of bioprocessing, Fast Trak scientists can improve productivity with attention to costs and regulatory compliance. Biomanufacturers working with Fast Trak maintain control over their intellectual property and can place “people-in-plant” for full understanding of the process.
 
The site utilizes Cytiva’s Figurate automation platform that includes exceptional control and communication capabilities which can turn data insights into productive outcomes for both upstream and downstream processes efficiency gains.
 
More than 70 percent of the clinical trials planned for the U.S. in 2020 will be Phase I and II, with over 50% of companies outsourcing at least some bioprocessing, and 19% outsourcing more than half. The upgraded Fast Trak cGMP facility has capacity to serve this growing need from small to mid-sized biotechnology companies.